Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 89 entries
Sorted by: Best Match Show Resources per page
Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1.

PloS one

Ide T, Eguchi Y, Harada M, Ishii K, Morita M, Morita Y, Sugiyama G, Fukushima H, Yano Y, Noguchi K, Nakamura H, Hisatomi J, Kumemura H, Shirachi M, Iwane S, Okada M, Honma Y, Arinaga-Hino T, Miyajima I, Ogata K, Kuwahara R, Amano K, Kawaguchi T, Kuromatsu R, Torimura T.
PMID: 27684567
PLoS One. 2016 Sep 29;11(9):e0163884. doi: 10.1371/journal.pone.0163884. eCollection 2016.

BACKGROUND: The aim of this study was to evaluate the efficacy of daclatasvir plus asunaprevir therapy in patients infected with hepatitis C virus and determine its relevance to resistant variants.METHODS: A total of 629 consecutive patients infected with hepatitis...

Cite
Ide T, Eguchi Y, Harada M, et al. Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. PLoS One. 2016;11(9):e0163884doi: 10.1371/journal.pone.0163884.
Ide, T., Eguchi, Y., Harada, M., Ishii, K., Morita, M., Morita, Y., Sugiyama, G., Fukushima, H., Yano, Y., Noguchi, K., Nakamura, H., Hisatomi, J., Kumemura, H., Shirachi, M., Iwane, S., Okada, M., Honma, Y., Arinaga-Hino, T., Miyajima, I., Ogata, K., Kuwahara, R., Amano, K., Kawaguchi, T., Kuromatsu, R., Torimura, T. (2016). Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. PloS one, 11(9), e0163884. https://doi.org/10.1371/journal.pone.0163884
Ide, Tatsuya, et al. "Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1." PloS one vol. 11,9 (2016): e0163884. doi: https://doi.org/10.1371/journal.pone.0163884
Ide T, Eguchi Y, Harada M, Ishii K, Morita M, Morita Y, Sugiyama G, Fukushima H, Yano Y, Noguchi K, Nakamura H, Hisatomi J, Kumemura H, Shirachi M, Iwane S, Okada M, Honma Y, Arinaga-Hino T, Miyajima I, Ogata K, Kuwahara R, Amano K, Kawaguchi T, Kuromatsu R, Torimura T. Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. PLoS One. 2016 Sep 29;11(9):e0163884. doi: 10.1371/journal.pone.0163884. eCollection 2016. PMID: 27684567; PMCID: PMC5042440.
Copy Download .nbib Format: NLM
Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy.

Hepatology research : the official journal of the Japan Society of Hepatology

Uemura H, Uchida Y, Kouyama JI, Naiki K, Yamaba S, Fuchigami A, Saito Y, Shiokawa K, Fujii Y, Uchiya H, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S.
PMID: 28884930
Hepatol Res. 2018 Mar;48(4):233-243. doi: 10.1111/hepr.12980. Epub 2017 Oct 20.

AIM: To improve the therapeutic efficacy of sofosbuvir/ledipasvir (SOF/LDV) for the retreatment of patients after daclatasvir/asunaprevir (DCV/ASV), a customized therapy with or without lead-in interferon (IFN)-β injections was formulated according to the types of resistance-associated substitutions (RAS) in the...

Cite
Uemura H, Uchida Y, Kouyama JI, et al. Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy. Hepatol Res. 2017;48(4):233-243doi: 10.1111/hepr.12980.
Uemura, H., Uchida, Y., Kouyama, J. I., Naiki, K., Yamaba, S., Fuchigami, A., Saito, Y., Shiokawa, K., Fujii, Y., Uchiya, H., Nakazawa, M., Ando, S., Nakao, M., Motoya, D., Sugawara, K., Inao, M., Imai, Y., Nakayama, N., Tomiya, T., & Mochida, S. (2018). Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy. Hepatology research : the official journal of the Japan Society of Hepatology, 48(4), 233-243. https://doi.org/10.1111/hepr.12980
Uemura, Hayato, et al. "Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy." Hepatology research : the official journal of the Japan Society of Hepatology vol. 48,4 (2018): 233-243. doi: https://doi.org/10.1111/hepr.12980
Uemura H, Uchida Y, Kouyama JI, Naiki K, Yamaba S, Fuchigami A, Saito Y, Shiokawa K, Fujii Y, Uchiya H, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S. Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy. Hepatol Res. 2018 Mar;48(4):233-243. doi: 10.1111/hepr.12980. Epub 2017 Oct 20. PMID: 28884930.
Copy Download .nbib Format: NLM
Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir.

Case reports in gastroenterology

Baba H, Tajiri K, Nagata K, Kawai K, Minemura M, Sugiyama T.
PMID: 27504082
Case Rep Gastroenterol. 2016 Jul 08;10(2):352-9. doi: 10.1159/000447486. eCollection 2016.

Daclatasvir (DCV) and asunaprevir (ASV) are direct-acting antivirals (DAAs) used in the treatment of chronic hepatitis C virus (HCV) infection. Combined therapy with DCV and ASV shows high efficacy and safety even in patients with cirrhosis. We encountered a...

Cite
Baba H, Tajiri K, Nagata K, et al. Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir. Case Rep Gastroenterol. 2016;10(2):352-9doi: 10.1159/000447486.
Baba, H., Tajiri, K., Nagata, K., Kawai, K., Minemura, M., & Sugiyama, T. (2016). Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir. Case reports in gastroenterology, 10(2), 352-9. https://doi.org/10.1159/000447486
Baba, Hayato, et al. "Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir." Case reports in gastroenterology vol. 10,2 (2016): 352-9. doi: https://doi.org/10.1159/000447486
Baba H, Tajiri K, Nagata K, Kawai K, Minemura M, Sugiyama T. Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir. Case Rep Gastroenterol. 2016 Jul 08;10(2):352-9. doi: 10.1159/000447486. eCollection 2016. PMID: 27504082; PMCID: PMC4965544.
Copy Download .nbib Format: NLM
Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?.

World journal of hepatology

Pipili C, Cholongitas E.
PMID: 26140081
World J Hepatol. 2015 Jun 28;7(12):1606-16. doi: 10.4254/wjh.v7.i12.1606.

The first generation direct antiviral agents (DAAs) highlighted substantial prognosis improvement among liver transplant (LT) candidates and recipients with recurrent hepatitis C virus (HCV) infection. During 2014, second generation DAAs are associated with high sustained virological response rates (>...

Cite
Pipili C, Cholongitas E. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?. World J Hepatol. 2015;7(12):1606-16doi: 10.4254/wjh.v7.i12.1606.
Pipili, C., & Cholongitas, E. (2015). Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?. World journal of hepatology, 7(12), 1606-16. https://doi.org/10.4254/wjh.v7.i12.1606
Pipili, Chrysoula, and Cholongitas, Evangelos. "Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?." World journal of hepatology vol. 7,12 (2015): 1606-16. doi: https://doi.org/10.4254/wjh.v7.i12.1606
Pipili C, Cholongitas E. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?. World J Hepatol. 2015 Jun 28;7(12):1606-16. doi: 10.4254/wjh.v7.i12.1606. PMID: 26140081; PMCID: PMC4483543.
Copy Download .nbib Format: NLM
Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?.

World journal of virology

Kanda T, Nakamoto S, Yokosuka O.
PMID: 26279979
World J Virol. 2015 Aug 12;4(3):178-84. doi: 10.5501/wjv.v4.i3.178.

In 2009, several groups reported that interleukin-28B (IL28B) genotypes are associated with the response to peginterferon plus ribavirin therapy for chronic hepatitis C virus (HCV) infection in a genome-wide association study, although the mechanism of this association is not...

Cite
Kanda T, Nakamoto S, Yokosuka O. Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?. World J Virol. 2015;4(3):178-84doi: 10.5501/wjv.v4.i3.178.
Kanda, T., Nakamoto, S., & Yokosuka, O. (2015). Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?. World journal of virology, 4(3), 178-84. https://doi.org/10.5501/wjv.v4.i3.178
Kanda, Tatsuo, et al. "Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?." World journal of virology vol. 4,3 (2015): 178-84. doi: https://doi.org/10.5501/wjv.v4.i3.178
Kanda T, Nakamoto S, Yokosuka O. Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?. World J Virol. 2015 Aug 12;4(3):178-84. doi: 10.5501/wjv.v4.i3.178. PMID: 26279979; PMCID: PMC4534809.
Copy Download .nbib Format: NLM
Real-world safety and efficacy of sofosbuvir and ledipasvir for elderly patients.

JGH open : an open access journal of gastroenterology and hepatology

Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K.
PMID: 30619941
JGH Open. 2018 Sep 19;2(6):300-306. doi: 10.1002/jgh3.12088. eCollection 2018 Dec.

BACKGROUND AND AIM: In September 2015, sofosbuvir and ledipasvir were approved for clinical use in Japan for patients infected with genotype 1 hepatitis C virus. We conducted a postmarketing prospective cohort study to elucidate the safety and efficacy of...

Cite
Tamai H, Shingaki N, Ida Y, et al. Real-world safety and efficacy of sofosbuvir and ledipasvir for elderly patients. JGH Open. 2018;2(6):300-306doi: 10.1002/jgh3.12088.
Tamai, H., Shingaki, N., Ida, Y., Shimizu, R., Maeshima, S., Okamura, J., Kawashima, A., Nakao, T., Hara, T., Matsutani, H., Nishikawa, I., & Higashi, K. (2018). Real-world safety and efficacy of sofosbuvir and ledipasvir for elderly patients. JGH open : an open access journal of gastroenterology and hepatology, 2(6), 300-306. https://doi.org/10.1002/jgh3.12088
Tamai, Hideyuki, et al. "Real-world safety and efficacy of sofosbuvir and ledipasvir for elderly patients." JGH open : an open access journal of gastroenterology and hepatology vol. 2,6 (2018): 300-306. doi: https://doi.org/10.1002/jgh3.12088
Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K. Real-world safety and efficacy of sofosbuvir and ledipasvir for elderly patients. JGH Open. 2018 Sep 19;2(6):300-306. doi: 10.1002/jgh3.12088. eCollection 2018 Dec. PMID: 30619941; PMCID: PMC6308062.
Copy Download .nbib Format: NLM
Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature.

Oncotarget

Haga Y, Kanda T, Yasui S, Nakamura M, Ooka Y, Takahashi K, Wu S, Nakamoto S, Arai M, Chiba T, Maruyama H, Yokosuka O, Takada N, Moriyama M, Imazeki F, Kato N.
PMID: 29435197
Oncotarget. 2017 Dec 29;9(4):5509-5513. doi: 10.18632/oncotarget.23768. eCollection 2018 Jan 12.

BACKGROUND: Interferon-free treatment results in higher sustained virologic response (SVR) rates, with no serious adverse events in hepatitis C virus (HCV)-infected patients. However, in some patients with treatment-failure in HCV NS5A inhibitor-including interferon-free regimens, the treatment-emergent HCV NS5A resistance-associated...

Cite
Haga Y, Kanda T, Yasui S, et al. Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. Oncotarget. 2017;9(4):5509-5513doi: 10.18632/oncotarget.23768.
Haga, Y., Kanda, T., Yasui, S., Nakamura, M., Ooka, Y., Takahashi, K., Wu, S., Nakamoto, S., Arai, M., Chiba, T., Maruyama, H., Yokosuka, O., Takada, N., Moriyama, M., Imazeki, F., & Kato, N. (2018). Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. Oncotarget, 9(4), 5509-5513. https://doi.org/10.18632/oncotarget.23768
Haga, Yuki, et al. "Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature." Oncotarget vol. 9,4 (2018): 5509-5513. doi: https://doi.org/10.18632/oncotarget.23768
Haga Y, Kanda T, Yasui S, Nakamura M, Ooka Y, Takahashi K, Wu S, Nakamoto S, Arai M, Chiba T, Maruyama H, Yokosuka O, Takada N, Moriyama M, Imazeki F, Kato N. Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. Oncotarget. 2017 Dec 29;9(4):5509-5513. doi: 10.18632/oncotarget.23768. eCollection 2018 Jan 12. PMID: 29435197; PMCID: PMC5797068.
Copy Download .nbib Format: NLM
Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C.

Hepatology research : the official journal of the Japan Society of Hepatology

Ueda Y, Kaido T, Hatano E, Ohtsuru S, Uemoto S.
PMID: 25704315
Hepatol Res. 2015 Dec;45(13):1360-2. doi: 10.1111/hepr.12509. Epub 2015 Apr 27.

Severe cholestatic hepatitis C (SCH) is a unique variant of recurrent hepatitis C that occurs after liver transplantation. Unfortunately, the prognosis of SCH is poor, and interferon (IFN) therapy has been reported to not improve the prognosis. We herein...

Cite
Ueda Y, Kaido T, Hatano E, et al. Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C. Hepatol Res. 2015;45(13):1360-2doi: 10.1111/hepr.12509.
Ueda, Y., Kaido, T., Hatano, E., Ohtsuru, S., & Uemoto, S. (2015). Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C. Hepatology research : the official journal of the Japan Society of Hepatology, 45(13), 1360-2. https://doi.org/10.1111/hepr.12509
Ueda, Yoshihide, et al. "Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C." Hepatology research : the official journal of the Japan Society of Hepatology vol. 45,13 (2015): 1360-2. doi: https://doi.org/10.1111/hepr.12509
Ueda Y, Kaido T, Hatano E, Ohtsuru S, Uemoto S. Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C. Hepatol Res. 2015 Dec;45(13):1360-2. doi: 10.1111/hepr.12509. Epub 2015 Apr 27. PMID: 25704315.
Copy Download .nbib Format: NLM
Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation.

Hepatology research : the official journal of the Japan Society of Hepatology

Honda M, Sugawara Y, Watanabe T, Tateyama M, Tanaka M, Uchida K, Kawabata S, Yoshii D, Miura K, Isono K, Hayashida S, Ohya Y, Yamamoto H, Sasaki Y, Inomata Y.
PMID: 28002876
Hepatol Res. 2017 Oct;47(11):1147-1154. doi: 10.1111/hepr.12853. Epub 2017 Jan 17.

AIM: The development of direct-acting oral agents has dramatically changed the treatment strategy of hepatitis C virus (HCV) infection. Here we aimed to reveal the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) for recurrent HCV genotype 1...

Cite
Honda M, Sugawara Y, Watanabe T, et al. Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation. Hepatol Res. 2017;47(11):1147-1154doi: 10.1111/hepr.12853.
Honda, M., Sugawara, Y., Watanabe, T., Tateyama, M., Tanaka, M., Uchida, K., Kawabata, S., Yoshii, D., Miura, K., Isono, K., Hayashida, S., Ohya, Y., Yamamoto, H., Sasaki, Y., & Inomata, Y. (2017). Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation. Hepatology research : the official journal of the Japan Society of Hepatology, 47(11), 1147-1154. https://doi.org/10.1111/hepr.12853
Honda, Masaki, et al. "Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation." Hepatology research : the official journal of the Japan Society of Hepatology vol. 47,11 (2017): 1147-1154. doi: https://doi.org/10.1111/hepr.12853
Honda M, Sugawara Y, Watanabe T, Tateyama M, Tanaka M, Uchida K, Kawabata S, Yoshii D, Miura K, Isono K, Hayashida S, Ohya Y, Yamamoto H, Sasaki Y, Inomata Y. Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation. Hepatol Res. 2017 Oct;47(11):1147-1154. doi: 10.1111/hepr.12853. Epub 2017 Jan 17. PMID: 28002876.
Copy Download .nbib Format: NLM
Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C.

Biomedicines

Takakusagi S, Sato K, Marubashi K, Kizawa K, Kosone T, Kakizaki S, Takagi H, Uraoka T.
PMID: 34201309
Biomedicines. 2021 Jun 08;9(6). doi: 10.3390/biomedicines9060660.

The clinical significance of mac-2 binding protein glycosylation isomer (M2BPGi) levels based on virological responses due to antiviral therapy has not been fully evaluated. We compared the change before and 24 weeks after the therapy with daclatasvir and asunaprevir...

Cite
Takakusagi S, Sato K, Marubashi K, et al. Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines. 2021;9(6)doi: 10.3390/biomedicines9060660.
Takakusagi, S., Sato, K., Marubashi, K., Kizawa, K., Kosone, T., Kakizaki, S., Takagi, H., & Uraoka, T. (2021). Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines, 9(6), . https://doi.org/10.3390/biomedicines9060660
Takakusagi, Satoshi, et al. "Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C." Biomedicines vol. 9,6 (2021). doi: https://doi.org/10.3390/biomedicines9060660
Takakusagi S, Sato K, Marubashi K, Kizawa K, Kosone T, Kakizaki S, Takagi H, Uraoka T. Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines. 2021 Jun 08;9(6). doi: 10.3390/biomedicines9060660. PMID: 34201309; PMCID: PMC8227298.
Copy Download .nbib Format: NLM
Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis.

Hepatology research : the official journal of the Japan Society of Hepatology

Ogawa E, Furusyo N, Yamashita N, Kawano A, Takahashi K, Dohmen K, Nakamuta M, Satoh T, Nomura H, Azuma K, Koyanagi T, Kotoh K, Shimoda S, Kajiwara E, Hayashi J.
PMID: 27142311
Hepatol Res. 2017 Mar;47(3):E120-E131. doi: 10.1111/hepr.12738. Epub 2016 Jun 10.

AIM: The aim of this study was to evaluate the efficacy and safety of 24-week daclatasvir (NS5A inhibitor) plus asunaprevir (NS3/4 A protease inhibitor) treatment for elderly patients with hepatitis C virus (HCV) genotype 1b infection.METHODS: This prospective, multicenter...

Cite
Ogawa E, Furusyo N, Yamashita N, et al. Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis. Hepatol Res. 2016;47(3):E120-E131doi: 10.1111/hepr.12738.
Ogawa, E., Furusyo, N., Yamashita, N., Kawano, A., Takahashi, K., Dohmen, K., Nakamuta, M., Satoh, T., Nomura, H., Azuma, K., Koyanagi, T., Kotoh, K., Shimoda, S., Kajiwara, E., Hayashi, J. (2017). Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis. Hepatology research : the official journal of the Japan Society of Hepatology, 47(3), E120-E131. https://doi.org/10.1111/hepr.12738
Ogawa, Eiichi, et al. "Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis." Hepatology research : the official journal of the Japan Society of Hepatology vol. 47,3 (2017): E120-E131. doi: https://doi.org/10.1111/hepr.12738
Ogawa E, Furusyo N, Yamashita N, Kawano A, Takahashi K, Dohmen K, Nakamuta M, Satoh T, Nomura H, Azuma K, Koyanagi T, Kotoh K, Shimoda S, Kajiwara E, Hayashi J. Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis. Hepatol Res. 2017 Mar;47(3):E120-E131. doi: 10.1111/hepr.12738. Epub 2016 Jun 10. PMID: 27142311.
Copy Download .nbib Format: NLM
Treating hepatitis C - what's new?.

Australian prescriber

Thompson AJ, Holmes JA.
PMID: 26843711
Aust Prescr. 2015 Dec;38(6):191-7. doi: 10.18773/austprescr.2015.068. Epub 2015 Sep 18.

Chronic hepatitis C infection causes cirrhosis, liver failure and hepatocellular carcinoma, and is the most common indication for liver transplantation. Hepatitis C is curable and complications can be prevented. Until recently, treatment regimens involved peginterferon alfa. Although effective, their...

Cite
Thompson AJ, Holmes JA. Treating hepatitis C - what's new?. Aust Prescr. 2015;38(6):191-7doi: 10.18773/austprescr.2015.068.
Thompson, A. J., & Holmes, J. A. (2015). Treating hepatitis C - what's new?. Australian prescriber, 38(6), 191-7. https://doi.org/10.18773/austprescr.2015.068
Thompson, Alex J, and Holmes, Jacinta A. "Treating hepatitis C - what's new?." Australian prescriber vol. 38,6 (2015): 191-7. doi: https://doi.org/10.18773/austprescr.2015.068
Thompson AJ, Holmes JA. Treating hepatitis C - what's new?. Aust Prescr. 2015 Dec;38(6):191-7. doi: 10.18773/austprescr.2015.068. Epub 2015 Sep 18. PMID: 26843711; PMCID: PMC4674032.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 89 entries